Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution
Grace R. Anderson, Peter Winter, Kevin Lin, et al.
Cell Reports (2017) Vol. 20, Iss. 4, pp. 999-1015
Open Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
Jimin Yuan, Xiaoduo Dong, Jiajun Yap, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 357
Therapeutic strategies to target RAS-mutant cancers
Meagan B. Ryan, Ryan B. Corcoran
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 11, pp. 709-720
Closed Access | Times Cited: 340
SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
Carmine Fedele, Hao Ran, Brian Diskin, et al.
Cancer Discovery (2018) Vol. 8, Iss. 10, pp. 1237-1249
Open Access | Times Cited: 268
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
Carmine Fedele, Shuai Li, Kai Wen Teng, et al.
The Journal of Experimental Medicine (2020) Vol. 218, Iss. 1
Open Access | Times Cited: 200
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Mı́riam Molina-Arcas, Christopher Moore, Sareena Rana, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 510
Open Access | Times Cited: 198
Illuminating the Onco-GPCRome: Novel G protein–coupled receptor-driven oncocrine networks and targets for cancer immunotherapy
Victoria H. Wu, Huwate Yeerna, Nijiro Nohata, et al.
Journal of Biological Chemistry (2019) Vol. 294, Iss. 29, pp. 11062-11086
Open Access | Times Cited: 160
CRISPR–Cas: a tool for cancer research and therapeutics
Hao Yin, Wen Xue, Daniel G. Anderson
Nature Reviews Clinical Oncology (2019) Vol. 16, Iss. 5, pp. 281-295
Closed Access | Times Cited: 155
MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function
Ayaka Sugiura, Gabriela Andrejeva, Kelsey Voss, et al.
Immunity (2021) Vol. 55, Iss. 1, pp. 65-81.e9
Open Access | Times Cited: 134
Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials
Yanlin Song, Zhenfei Bi, Yu Liu, et al.
Genes & Diseases (2022) Vol. 10, Iss. 1, pp. 76-88
Open Access | Times Cited: 112
Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors
Grace R. Anderson, Suzanne E. Wardell, Merve Çakır, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 119
Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity
Ryan S. Soderquist, Lorin Crawford, Esther Liu, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 108
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers
Irem Ozkan‐Dagliyan, J. Nathaniel Diehl, Samuel D. George, et al.
Cell Reports (2020) Vol. 31, Iss. 11, pp. 107764-107764
Open Access | Times Cited: 88
Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers
Rita Sulahian, Jason J. Kwon, Katherine H. Walsh, et al.
Cell Reports (2019) Vol. 29, Iss. 1, pp. 118-134.e8
Open Access | Times Cited: 79
Global Regulation of the Histone Mark H3K36me2 Underlies Epithelial Plasticity and Metastatic Progression
Salina Yuan, Ramakrishnan Natesan, Francisco J. Sánchez‐Rivera, et al.
Cancer Discovery (2020) Vol. 10, Iss. 6, pp. 854-871
Open Access | Times Cited: 72
Frequency-Dependent Ecological Interactions Increase the Prevalence, and Shape the Distribution, of Preexisting Drug Resistance
Jeff Maltas, Dagim Shiferaw Tadele, Arda Durmaz, et al.
PRX Life (2024) Vol. 2, Iss. 2
Open Access | Times Cited: 9
RAS variant signalling
Stephanie Mo, Judy M. Coulson, Ian A. Prior
Biochemical Society Transactions (2018) Vol. 46, Iss. 5, pp. 1325-1332
Open Access | Times Cited: 80
PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers
Zheng Zhong, Sugunavathi Sepramaniam, Xin Hui Chew, et al.
Oncogene (2019) Vol. 38, Iss. 40, pp. 6662-6677
Open Access | Times Cited: 75
Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability
Hema Adhikari, Christopher M. Counter
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 74
The Function of RAS Mutation in Cancer and Advances in its Drug Research
Shijie Chen, Fengyang Li, Dan Xu, et al.
Current Pharmaceutical Design (2019) Vol. 25, Iss. 10, pp. 1105-1114
Closed Access | Times Cited: 64
NRASStatus Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS–MAPK Pathway in Neuroblastoma
Ivette Valencia-Sama, Yagnesh Ladumor, Lynn Kee, et al.
Cancer Research (2020) Vol. 80, Iss. 16, pp. 3413-3423
Open Access | Times Cited: 58
Precision Therapy in RAS Mutant Colorectal Cancer
Rodrigo Dienstmann, Kate Connor, Annette T. Byrne, et al.
Gastroenterology (2020) Vol. 158, Iss. 4, pp. 806-811
Open Access | Times Cited: 50
Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer
Nancy Gavert, Yaara Zwang, Roi Weiser, et al.
Nature Cancer (2022) Vol. 3, Iss. 2, pp. 219-231
Closed Access | Times Cited: 36
Immune Resistance and EGFR Antagonists in Colorectal Cancer
Guido Giordano, Andrea Remo, Almudena Porrás, et al.
Cancers (2019) Vol. 11, Iss. 8, pp. 1089-1089
Open Access | Times Cited: 49
Ras assemblies and signaling at the membrane
Ruth Nussinov, Chung‐Jung Tsai, Hyunbum Jang
Current Opinion in Structural Biology (2020) Vol. 62, pp. 140-148
Closed Access | Times Cited: 41
The Role of Wild-Type RAS in Oncogenic RAS Transformation
Erin Sheffels, Robert L. Kortum
Genes (2021) Vol. 12, Iss. 5, pp. 662-662
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top